NEW YORK – Bio-Techne said on Tuesday that it has inked a development and license agreement with Thermo Fisher Scientific to complete development of and commercialize Bio-Techne's ExoTru kidney transplant rejection test, a multigene urine-based assay.
The noninvasive, liquid biopsy assay has the potential to discriminate between T-cell mediated rejection and antibody mediated rejection, which is critical to improving patient management and outcomes, Minneapolis-based Bio-Techne said, adding that the test provides critical allograft health information to assist clinician decision-making in managing kidney transplant patients.
Financial and other terms of the agreement were not disclosed.
With its established transplant center relationships, Thermo Fisher is the ideal partner to develop, commercialize, and drive adoption of the assay, according to Bio-Techne.
Bio-Techne's Exosome Diagnostics business has been developing the assay in collaboration with the Transplantation Research Center at Brigham and Women's Hospital, Harvard Medical School.